To include your compound in the COVID-19 Resource Center, submit it here.

Biogen climbs as Spinraza sales top consensus

Biogen Inc. (NASDAQ:BIIB) gained $10.03 to $286.89 after it reported 1Q17 earnings that beat a consensus estimate, including stronger than expected sales of Spinraza nusinersen. The company reported $47.4 million in sales of the spinal muscular atrophy treatment, up from

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE